Although nonsense suppression therapy (Ataluren) and exon skipping (Eteplirsen, Drisapersen) are two different pharmacological strategies for different patients with DMD, for both strategies the target is the synthesis of a partially functional dystrophin. This evidence concerns the gene DMD and Duchenne muscular dystrophy.